Inogen hits profitability milestone, grows TAM sixfold with new respiratory products

BEVERLY, Mass. – President and CEO Kevin Smith says 2025 marked a critical turning point for Inogen, with the company delivering adjusted EBITDA profitability for the first time since 2021. Underscoring that progress, Inogen has authorized a $30 million share repurchase program spanning 2026–27.

For the full year, Inogen reported positive adjusted EBITDA of $2.7 million, signaling stabilization after several years of restructuring and portfolio expansion.

“The share repurchase program reflects our confidence in our strategy, our flexibility to deploy capital and our commitment to enhance shareholder value,” Smith said during a call to discuss fourth quarter and full-year 2025 financial results. “The trajectory is clear. We've returned to adjusted EBITDA profitability, dramatically reduced our losses and strengthened our cash position. As we drive improved revenue performance in 2026, we expect to see meaningful operating leverage flow through to the bottom line. We're building a sustainably profitable business.”

Diversification strategy expands Inogen’s market opportunity

In recent years, Inogen has deliberately moved away from being a single‑product, single‑disease‑state company focused solely on portable oxygen concentrators (POCs). The company now offers a broader respiratory portfolio that includes:

• Simeox, an airway clearance device (limited U.S. release)
• Voxi 5, Inogen’s first stationary oxygen concentrator
• Aurora CPAP masks, marking Inogen’s entry into sleep therapy
• A new self‑service digital platform for patients

“For years, Inogen was synonymous with portable oxygen concentrators,” Smith said. “While that remains our core strength, we've now established a multiproduct portfolio spanning four distinct areas of respiratory care, oxygen therapy, sleep therapy, airway clearance and digital health solutions. This diversification significantly expands our addressable market, derisks our business model and positions us to better serve patients across the full respiratory continuum.”

With this broadened portfolio, Inogen estimates its total addressable market has expanded from about $400 million to roughly $3.4 billion.

“This sixfold expansion in the estimated TAM, coupled with accelerated growth rates has the potential to change our financial trajectory and long-term value creation,” Smith said.

Ongoing innovation targets margin improvement

Looking ahead, Inogen plans to launch at least one new product per year, a cadence the company believes will support revenue growth and profitability.

“And critically, we expect these new launches to be gross margin accretive, as we increasingly focus on higher-margin, clinically differentiated solutions that address unmet needs across the respiratory care continuum,” Smith said.

Also heard during the call

Go-to-market strategy for Aurora masks

Inogen continues to build its dedicated sales organization for sleep therapy but also sees strong opportunity to leverage long-standing POC relationships.

“It is a $2.2 billion market here in the United States for the masks,” Smith said. “That's a repeatable business. Once a patient gets satisfied, they like a mask, they get a good night sleep, it's hard to get them off of that mask. And the patient study that we did demonstrates that we're able to bring something that's competitive. And every 1% growth in that market is about a $20 million opportunity for Inogen.”

Q4 revenue softness expected to rebound

The company experienced a shift of large customer orders out of Q4 and into early 2026, driven by customer capital constraints and year‑end budget limitations.

“We expect them to materialize as customer budgets are approved through the first half of 2026,” said Michael Bourque, executive vice president and CFO.

Long-term financial targets

Inogen sees a path to achieving high single-digit revenue growth and reaching 10% or better adjusted EBITDA over the next three to five years.